



AAVLD – AST Mini-symposium

Brian Lubbers, DVM, PhD, DACVCP
blubbers@vet.k-state.edu

Kansas State Veterinary
DIAGNOSTIC LABORATORY

Speaker Disclosure – Brian Lubbers

FINANCIAL DISCLOSURE:

- Employee – Kansas State Veterinary Diagnostic Laboratory
- Speaker / Consulting Engagement – Merck Animal Health; Boehringer Ingelheim Vetmedica
- Research Support – Merck Animal Health; Zoetis

UNLABELED/ UNAPPROVED USES DISCLOSURE:

- NONE

**** THERAPEUTIC USES DISCLOSURE:**

- ANY reference to a therapeutic is for illustrative purposes and is NOT an endorsement of a specific product

Other Disclosure

*Much of this presentation is **MY PERSPECTIVE**,
based on my training and experiences.*

*I do not presume to tell other laboratories how to
operate. In fact, I would not encourage you to adopt /
do anything that is outside your “comfort zone”.*

*However, I encourage **OPEN DISCUSSION** about
how we can all get better.....*

MY PERSPECTIVE

- Clinical Veterinarian
- Clinical Pharmacologist
- Microbiology Laboratory Section Head
- CLSI – VAST volunteer




From: OpenTip.com

Kansas State Veterinary
DIAGNOSTIC LABORATORY

What I want you to know from today

- The given factors that a veterinarian will consider when selecting an antimicrobial are NUMEROUS
 - There are opportunities for diagnostic labs to assist



What I want you to know from today

- CLSI is NOT a secretive organization conspiring against microbiology lab personnel
 - There are opportunities for diagnostic labs to assist



<https://thoughtcatalog.com/jacob-geers/2016/04/creepy-stories-of-the-real-men-in-black/>

Kansas State Veterinary
DIAGNOSTIC LABORATORY

Kansas State Veterinary
DIAGNOSTIC LABORATORY



What do *you* want to get from today?

Kansas State Veterinary
DIAGNOSTIC LABORATORY



Antibiotic Stuff

Antibiotic Stewardship and Diagnostic Testing???

NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

Clinical Infectious Diseases

IDSA GUIDELINE

 IDSA
 Infectious Diseases Society of America

 hivma
 the medicine association

 COLFID

Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America

Tamar F. Barlam,^{1,4} Sara E. Cosgrove,^{2,4} Lilian M. Abbo,² Conan MacDougall,⁴ Audrey N. Schuetz,² Edward J. Septimus,⁴ Arjun Srinivasan,⁷ Timothy H. Dellit,⁴
 Yngve T. Falck-Ytter,⁴ Neil O. Fishman,⁸ Cindy W. Hamilton,¹¹ Timothy C. Jenkins,¹² Pamela A. Lipsett,¹³ Preeti N. Malani,¹⁴ Larissa S. May,¹⁵
 Gregory J. Moran,¹⁶ Melinda M. Neuhauser,¹⁷ Jason G. Newland,¹⁸ Christopher A. Ohl,¹⁹ Matthew H. Samore,²⁰ Susan K. Seo,²¹ and Kavita K. Trivedi²²



The Core Elements of
Outpatient Antibiotic Stewardship

Kansas State Veterinary
DIAGNOSTIC LABORATORY


Antibiotic Stewardship in Veterinary Medicine

- Actions veterinarians take individually and as a profession to preserve the effectiveness and availability of antimicrobial drugs through conscientious oversight and responsible medical decision-making while safeguarding animal, public and environmental health.
- Core principles
 - Commit to stewardship
 - Advocate for a system of care to prevent common diseases
 - Select and use antimicrobials judiciously
 - Evaluate antimicrobial use practices
 - Educate and build expertise

STEWARDSHIP FALLS ON THE VETERINARIAN!!

<https://www.avma.org/KB/Policies/Pages/Antimicrobial-Stewardship-Definition-and-Core-Principles.aspx>

Antibiotic Stewardship in Veterinary Medicine



How veterinarians select antibiotics.....

- Is an antibiotic even necessary for this patient?



How veterinarians select antibiotics..... & how the micro lab can help!

- Is an antibiotic even necessary for this patient?



| | |
|-----------------|------------------------------------|
| Specimen Desc: | URINE |
| Organism Id: | ESCHERICHIA COLI (NON-HEMOLYTIC) |
| Comments: | -->10,000 cfu/ml |
| Received Date: | February 20, 2018 |
| Test Finalized: | February 22, 2018 |
| Update 1: | 2/21/2018, No growth at this time. |
| Update 2: | 2/22/2018, No growth. |

How veterinarians select antibiotics.....

- Is an antibiotic even necessary for this patient?

YES

- How do veterinarians select the most appropriate antibiotic?

The “best” antimicrobial.....

- is **Legal** to use in that patient,
- has a reasonable expectation of **Efficacy** and
- is reasonably **Safe** for the patient, the owner (or whoever is administering) and the end consumer (if the patient is a food animal).

The ideal antimicrobial is also **available** for prescribing, can be **readily administered** to the patient, is within the **financial constraints** of the owner and is **familiar** to the clinician.

- 1) Antimicrobial selection is NOT “cookie cutter”
- 2) It is a fluid process and requires consideration of the above in each and every case

Legal Use of Antimicrobials in Veterinary Medicine

- For food animals
 - Animal Medicinal Drug Use Clarification Act of 1994 [AMDUCA]
 - Animal Drug Availability Act of 1996
 - Veterinary Feed Directive

- FDA Guidance 209
- FDA Guidance 213
- Compliance Policy Guide Sec 615.115

Legal Use of Antimicrobials in Veterinary Medicine & how the micro lab can help!

- Animal Medicinal Drug Use Clarification Act
 - 21 CFR Part 530.41
 - The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in food-producing animals:
(BVL note -- only antibiotics listed here)
 1. Chloramphenicol
 2. Dimetridazole
 3. Ipronidazole
 4. Other nitroimidazoles
 5. Furazolidone
 6. Nitrofurazone
 7. Glycopeptides
- NEVER report for Food Animals**

Legal Use of Antimicrobials in Veterinary Medicine & how the micro lab can help!

- Animal Medicinal Drug Use Clarification Act
 - 21 CFR Part 530.41
 - The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in food-producing animals:
 1. Sulfonamide drugs in lactating dairy cattle
 - (except approved uses of sulfadimethoxine)
 2. Cephalosporins***
 - For disease prevention
 - Unapproved doses, routes, durations, frequencies
 - Not approved for that species / production class
 3. Fluoroquinolones

Conditionally report in
Food Animals??

What about reporting aminoglycosides?

Aminoglycoside Use in Cattle and Small Ruminants

Due to food safety concerns from extended withdrawal times and associated drug residue risks, the AVMA does not support the use of aminoglycosides in cattle or small ruminants except those products specifically approved by FDA for use in cattle or small ruminants.

Formerly titled "Aminoglycosides"



<https://www.avma.org/KB/Policies/Pages/Aminoglycoside%20Use%20in%20Cattle%20and%20Small%20Ruminants.aspx>

Kansas State Veterinary
DIAGNOSTIC LABORATORY

Legal Use of Antimicrobials in Veterinary Medicine

- What is a Food Animal?
 - Cattle, Swine, Chickens, Turkeys ★
 - Bear in zoo 🚫
 - Cervids ★
 - Game birds (pheasant, chukar, quail) ★
 - Llama & alpaca 🚫
 - Pot-bellied pigs ★
 - Pygmy goats ★
 - Rabbits ★
 - Sheep & Goats ★
 - Wild bear ★

Legal Use of Antimicrobials in Veterinary Medicine & how the micro lab can help!

- For companion animals
 - Animal Medicinal Drug Use Clarification Act of 1994
 - Veterinarian has virtually unlimited discretion – currently, however.....

 - Should we be reporting????
 - Carbapenems
 - Linezolid
 - Vancomycin

The “best” antimicrobial.....

- is **Legal** to use in that patient,
- has a reasonable expectation of **Efficacy** and
- is reasonably **Safe** for the patient, the owner (or whoever is administering) and the end consumer (if the patient is a food animal).

The ideal antimicrobial is also **available** for prescribing, can be **readily administered** to the patient, is within the **financial constraints** of the owner and is **familiar** to the clinician.

- 1) Antimicrobial selection is NOT “cookie cutter”
- 2) It is a fluid process and requires consideration of the above in each and every case


What factors would a veterinarian use to support efficacy, or lack of & how the micro lab can help!

- Empiric therapy – Before you have a pathogen identified
 - Antimicrobial spectrum
 - Site of infection
 - Cumulative antimicrobial susceptibility data
 - Non-response to prior therapy
- Definitive therapy – You have a “target” pathogen
 - Intrinsic resistance
 - Antimicrobial label
 - Clinical trials
 - Individual antimicrobial susceptibility report
 - Non-response to prior therapy

Intrinsic Resistance / Clinical Inefficacy

- Inherent or innate -- not acquired -- resistance to an antimicrobial or antimicrobial class. Susceptibility testing is unnecessary in cases of intrinsic resistance [or result reporting should be reflective].
- Common veterinary intrinsic / clinical resistances
 - *Proteus mirabilis*: tetracycline, tigecycline, nitrofurantoin, polymixin B
 - *Pseudomonas aeruginosa*: amp/amoxicillin, amp-sulbactam, amoxiclavulanate, cefotaxime, ceftriaxone, ertapenem, tetra/tigecycline, trimethoprim, TMS-SMZ, chloramphenicol
 - *Enterococcus* spp.: cephalosporins, aminoglycosides, clindamycin, trimethoprim, TMS-SMZ, fusidic acid
 - *Salmonella* spp.: aminoglycosides, 1st/2nd generation cephalosporins (cefazolin, cephalexin), cephamycins
 - Anaerobes: aminoglycosides
- Appendix B in M100 / Appendix B in VET08

Using Cumulative AST data to support efficacy



Standards for presenting cumulative AST data

- M39: Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data
- M39QG: Antibiograms: Developing Cumulative Reports for Your Clinicians

Analysis and Presentation of Cumulative Antibiograms: A New Consensus Guideline from the Clinical and Laboratory Standards Institute

Janet F. Hindler¹ and John Stelling²

¹University of California Los Angeles Medical Center, Los Angeles; and ²Brigham and Women's Hospital, Boston, Massachusetts

Clinical Infectious Diseases. 2007. 44: 867-873.

- Cumulative AST data are often used in human healthcare (and veterinary medicine) to prescribe empirical antimicrobial therapy

Intermountain Healthcare Southern Region Rural Hospitals 2014 ANTI BIOGRAM

Gram Negative Bacilli % Susceptible

| # Tests | Species/Organism | Amikacin | Amoxicillin/Clavulanic Acid | Ampicillin | Ampicillin/Sulbactam | Aztreonam | Cefazolin | Cefepime | Cefotaxime | Cefoxitin | Ceftazidime | Ceftriaxone | Cefuroxime | Ciprofloxacin | Ertapenem | Gentamicin | Imipenem | Levofloxacin | Meropenem | Nitrofurantoin % | Piperacillin/Tazobactam | Tetracycline | Tobramycin | Trimethoprim/Sulfamethoxazole |
|---------|------------------------|----------|-----------------------------|------------|----------------------|-----------|-----------|----------|------------|-----------|-------------|-------------|------------|---------------|-----------|------------|----------|--------------|-----------|------------------|-------------------------|--------------|------------|-------------------------------|
| 35 | Citrobacter species | 97 | 0 | 0 | 0 | 89 | 0 | 97 | 89 | 0 | 86 | 89 | 0 | 91 | 100 | 91 | 100 | 97 | 100 | 75 | 97 | 80 | 94 | 77 |
| 38 | Enterobacter cloacae | 100 | 0 | 0 | 0 | 89 | 0 | 97 | 95 | 0 | 89 | 89 | 0 | 100 | 100 | 97 | 100 | 100 | 100 | 11 | 89 | 87 | 97 | 89 |
| 787 | Escherchia coli | 99 | 83 | 58 | 62 | 97 | 88 | 98 | 98 | 93 | 98 | 98 | 94 | 85 | 100 | 94 | 100 | 85 | 100 | 98 | 97 | 79 | 95 | 78 |
| 45 | Klebsiella oxytoca | 100 | 98 | 0 | 74 | 93 | 44 | 100 | 100 | 91 | 100 | 100 | 93 | 93 | 100 | 100 | 100 | 96 | 100 | 76 | 100 | 87 | 100 | 87 |
| 131 | Klebsiella pneumoniae | 100 | 93 | 0 | 80 | 98 | 95 | 100 | 100 | 94 | 100 | 100 | 97 | 98 | 100 | 100 | 100 | 98 | 100 | 33 | 94 | 88 | 100 | 87 |
| 42 | Proteus mirabilis | 98 | 90 | 67 | 78 | 93 | 83 | 98 | 95 | 90 | 95 | 98 | 90 | 83 | 100 | 86 | 100 | 83 | 100 | 0 | 98 | 0 | 86 | 74 |
| 67 | Pseudomonas aeruginosa | 94 | | | | 82 | | 94 | 0 | | 94 | 0 | | 91 | | 84 | 96 | 93 | 99 | | 97 | | 99 | |

<https://intermountainphysician.org/gw/Antibiograms2/Rural%202014.pdf>

- **Caution:** extrapolation to an individual is only as good as the underlying patient population from which the cumulative data is drawn


Comparison of hospital-wide and age and location - stratified antibiograms of *S. aureus*, *E. coli*, and *S. pneumoniae*: age- and location-stratified antibiograms

Sanjeev K Swami¹ and Ritu Banerjee^{2*}

Conclusions: Stratified antibiograms reveal age - associated differences in susceptibility of *E. coli*, *S. aureus*, and *S. pneumoniae* that are obscured by hospital-wide antibiograms. Age-stratified antibiograms have potential to influence antibiotic selection.

Swami SK. 2013. Springerplus. 2; 63-67.

FIGURE 1. Number of invasive pneumococcal isolates and percentage of isolates that were nonsusceptible to penicillin, by geographic area* — United States, 1997




Kansas State Veterinary
DIAGNOSTIC LABORATORY


CDC. 1999. MMWR. 48; 656-661.

- **Caution:** extrapolation to an individual is only as good as the underlying patient population from which the cumulative data is drawn

Cow-Calf (n=63 isolates)



Feedlot (n=229 isolates)



Cumulative AST summaries

- Summaries from KSVDL diagnostic submissions
 - *Mannheimia haemolytica*
 - *Pasteurella multocida*
 - *Histophilus somni*
- Isolates recovered from bovine lung
 - Animal died of BRD
 - Likely received antimicrobial(s) ante-mortem
- Antimicrobials
 - Ceftiofur, Enrofloxacin, Florfenicol, Oxytetracycline, Penicillin, Spectinomycin, Tilmicosin




Kansas State Veterinary
DIAGNOSTIC LABORATORY

WHY ONLY THESE?

Mannheimia haemolytica

Oxytetracycline




Kansas State Veterinary
DIAGNOSTIC LABORATORY

Cumulative AST summaries

- Other uses....
 - Co-resistance / MDR
 - Cross-resistance



Mannheimia haemolytica Multi-drug resistance



Kansas State Veterinary
DIAGNOSTIC LABORATORY

Mannheimia haemolytica (n=1550 isolates)

| | | | | | | | | | |
|---------------|-----|----|----|-----|----|----|----|----|-----|
| tilmicosin | >64 | | | 1 | | 27 | 94 | 15 | 693 |
| | 64 | | | | 5 | 8 | 3 | 6 | 99 |
| | 32 | | | 8 | 4 | 1 | 3 | 4 | 53 |
| | 16 | | | 46 | 44 | 5 | 1 | 1 | 16 |
| | 8 | | 2 | 62 | 34 | 1 | 1 | 2 | |
| | ≤4 | 8 | 71 | 204 | 26 | | 2 | | |
| | | ≤1 | 2 | 4 | 8 | 16 | 32 | 64 | >64 |
| tulathromycin | | | | | | | | | |

83% - S/S or I/I or R/R

3.6% - S/R mismatch

The “best” antimicrobial.....

- is **Legal** to use in that patient,
- has a reasonable expectation of **Efficacy** and
- is reasonably **Safe** for the patient, the owner (or whoever is administering) and the end consumer (if the patient is a food animal).

The ideal antimicrobial is also **available** for prescribing, can be **readily administered** to the patient, is within the **financial constraints** of the owner and is **familiar** to the clinician.

- 1) Antimicrobial selection is NOT “cookie cutter”
- 2) It is a fluid process and requires consideration of the above in each and every case

Patient safety..... and how the micro lab can help??

- Overt toxicities??
 - Where do you draw the line????
 - Lincosamides in horses & rabbits
 - Tilmicosin (injectable) in pigs & goats
 - Sulfonamides in dogs

- AST results in alphabetical order????

| | Interpretation | MIC | Test Range |
|------------|----------------|---------|------------|
| AMIKACIN | S | ≤4.0000 | 4 - 32 |
| AMOXI/CLAV | S | ≤0.1200 | 0.12 - 1 |

Kansas State Veterinary
DIAGNOSTIC LABORATORY



For discussion....

A or B?

A or B?

History: Neonatal pot-bellied pig with diarrhea. *E. coli* isolated on culture.

| | Interpretation | MIC | Test Range |
|-------------------|----------------|------------|------------|
| AMPICILLIN | S | 2.0000 | 0.25 - 16 |
| CEFTIOFUR | NI | 0.5000 | 0.25 - 8 |
| CHLORTETRACYCLINE | NI | >8.0000 | 0.5 - 8 |
| CLINDAMYCIN | NI | >16.0000 | 0.25 - 16 |
| ENROFLOXACIN | NI | <=0.1200 | 0.12-2 |
| FLORFENICOL | NI | 2.0000 | 0.25-8 |
| GENTAMICIN | S | <=1.0000 | 1-16 |
| NEOMYCIN | NI | <=4.0000 | 4-32 |
| OXYTETRACYCLINE | NI | >8.0000 | 0.5-8 |
| PENICILLIN | NI | >8.0000 | 0.12-8 |
| SPECTINOMYCIN | NI | 16.0000 | 8-64 |
| SULFADIMETHOXINE | NI | <=256.0000 | 256 |
| TIAMULIN | NI | >32.0000 | 0.5-32 |
| TILMICOSIN | NI | 64.0000 | 4-64 |
| TRIMETH/SULFA | S | <=2.0000 | 2/38 |
| TULATHROMYCIN | NI | 8.0000 | 1-64 |
| TYLOSIN TARTRATE | NI | >32.0000 | 0.5-32 |

| | Interpretation | MIC | Test Range |
|---------------------|----------------|----------|----------------|
| AMIKACIN | S | <=4.0000 | 4 - 32 |
| AMOXI/CLAV | S | <=0.1200 | 0.12 - 1 |
| AMPICILLIN | NI | | 0.12 - 1 |
| CEFAZOLIN | S | <=1.0000 | 1 - 8 |
| CEFOVECIN | NI | <=0.2500 | 0.25 - 4 |
| CEFOXITIN | S | <=2.0000 | 2 - 16 |
| CEFPODOXIME | S | <=2.0000 | 2 - 16 |
| CEFTIOFUR | S | <=0.2500 | 0.25 - 4 |
| CEPHALOTHIN | S | <=2.0000 | 2 - 8 |
| CHLORAMPHENICOL | S | <=4.0000 | 4 - 16 |
| CLINDAMYCIN | S | <=0.5000 | 0.5 - 4 |
| DOXYCYCLINE | S | <=2.0000 | 2 - 8 |
| ENROFLOXACIN | S | <=0.2500 | 0.25 - 2 |
| ERYTHROMYCIN | S | <=0.5000 | 0.5 - 4 |
| GENTAMICIN | S | <=1.0000 | 1 - 8 |
| IMIPENEM | S | 2.0000 | 1 - 8 |
| MARBOFLOXACIN | S | <=0.2500 | 0.25 - 2 |
| OXACILLIN + 2% NACL | S | <=0.2500 | 0.25 - 4 |
| PENICILLIN | NI | | 0.06 - 8 |
| RIFAMPIN | NI | <=1.0000 | 1 - 2 |
| TICAR/CLAV ACID | S | <=8.0000 | 8/2 - 64/2 |
| TICARCILLIN | NI | | 8 - 64 |
| TRIMETH/SULFA | S | <=0.5000 | 0.5/9.5 - 2/38 |

Kansas State Veterinary
DIAGNOSTIC LABORATORY

A: Pot bellied pigs are considered food animals – avoid reporting prohibited drugs

| | Interpretation | MIC | Test Range |
|-------------------|----------------|------------|------------|
| AMPICILLIN | S | 2.0000 | 0.25 - 16 |
| CEFTIOFUR | NI | 0.5000 | 0.25 - 8 |
| CHLORTETRACYCLINE | NI | >8.0000 | 0.5 - 8 |
| CLINDAMYCIN | NI | >16.0000 | 0.25 - 16 |
| ENROFLOXACIN | NI | <=0.1250 | 0.12-2 |
| FLORFENICOL | NI | 0.0000 | 0.25-8 |
| GENTAMICIN | S | <=1.0000 | 1-16 |
| NEOMYCIN | S | <=4.0000 | 4-32 |
| OXYTETRACYCLINE | NI | >8.0000 | 0.5-8 |
| PENICILLIN | NI | >8.0000 | 0.12-8 |
| SPECTINOMYCIN | NI | 16.0000 | 8-64 |
| SULFADIMETHOXINE | NI | <=256.0000 | 256 |
| TIAMULIN | NI | >32.0000 | 0.5-32 |
| TILMICOSIN | NI | 64.0000 | 4-64 |
| TRIMETH/SULFA | S | <=2.0000 | 2/38 |
| TULATHROMYCIN | NI | 8.0000 | 1-64 |
| TYLOSIN TARTRATE | NI | >32.0000 | 0.5-32 |

| | Interpretation | MIC | Test Range |
|---------------------|----------------|----------|----------------|
| AMIKACIN | S | <=4.0000 | 4 - 32 |
| AMOXI/CLAV | S | <=0.1200 | 0.12 - 1 |
| AMPICILLIN | NI | | 0.12 - 1 |
| CEFAZOLIN | S | <=1.0000 | 1 - 8 |
| CEFOVECIN | NI | <=0.2500 | 0.25 - 4 |
| CEFOXITIN | S | <=2.0000 | 2 - 16 |
| CEFPODOXIME | S | <=2.0000 | 2 - 16 |
| CEFTIOFUR | S | <=0.2500 | 0.25 - 4 |
| CEPHALOTHIN | S | <=2.0000 | 2 - 8 |
| CHLORAMPHENICOL | S | <=4.0000 | 4 - 16 |
| CLINDAMYCIN | S | <=0.5000 | 0.5 - 4 |
| DOXYCYCLINE | S | <=2.0000 | 2 - 8 |
| ENROFLOXACIN | S | <=0.2500 | 0.25 - 2 |
| ERYTHROMYCIN | S | <=0.5000 | 0.5 - 4 |
| GENTAMICIN | S | <=1.0000 | 1 - 8 |
| IMIPENEM | S | 2.0000 | 1 - 8 |
| MARBOFLOXACIN | S | <=0.2500 | 0.25 - 2 |
| OXACILLIN + 2% NACL | S | <=0.2500 | 0.25 - 4 |
| PENICILLIN | NI | | 0.06 - 8 |
| RIFAMPIN | NI | <=1.0000 | 1 - 2 |
| TICAR/CLAV ACID | S | <=8.0000 | 8/2 - 64/2 |
| TICARCILLIN | NI | | 8 - 64 |
| TRIMETH/SULFA | S | <=0.5000 | 0.5/9.5 - 2/38 |

Kansas State Veterinary
DIAGNOSTIC LABORATORY

A or B?

History: 9 yr old DLH with clinical signs of UTI. *Enterococcus faecalis* isolated on culture.

| | Interpretation | MIC | Test Range |
|---------------------|----------------|-----------|---------------|
| AMIKACIN | R | | 16-32 |
| AMOXI/CLAV | S | 0.5000 | 0.25/0.12-8/4 |
| AMPICILLIN | S | 1.0000 | 0.25-8 |
| CHLORAMPHENICOL | S | <=8.0000 | 8-32 |
| DOXYCYCLINE | S | <=0.1200 | 0.12-0.5 |
| ENROFLOXACIN | I | 1.0000 | 0.25-4 |
| ERYTHROMYCIN | I | 1.0000 | 0.25-4 |
| GENTAMICIN | R | | 4-16 |
| IMIPENEM | S | <=1.0000 | 1-4 |
| MARBOFLOXACIN | I | 2.0000 | 1-4 |
| MINOCYCLINE | S | <=0.5000 | 0.5-2 |
| NITROFURATOIN | S | <=16.0000 | 16-64 |
| OXACILLIN + 2% NACL | NI | >2.0000 | 0.25-2 |
| PENICILLIN | S | 2.0000 | 0.06-8 |
| PRADOFLOXACIN | NI | <=0.2500 | 0.25-2 |
| RIFAMPIN | S | <=1.0000 | 1-2 |
| TETRACYCLINE | S | <=0.2500 | 0.25-1 |
| VANCOMYCIN | S | 2.0000 | 1-16 |

| | Interpretation | MIC | Test Range |
|---------------------|----------------|-----------|---------------|
| AMIKACIN | R | | 16-32 |
| AMOXI/CLAV | S | 0.5000 | 0.25/0.12-8/4 |
| AMPICILLIN | S | 1.0000 | 0.25-8 |
| CEFAZOLIN | R | >4.0000 | 2-4 |
| CEFOVECIN | NI | >8.0000 | 0.06-8 |
| CEFPODOXIME | NI | 4.0000 | 2-8 |
| CEPHALOTHIN | NI | >4.0000 | 2-4 |
| CHLORAMPHENICOL | S | <=8.0000 | 8-32 |
| CLINDAMYCIN | NI | >4.0000 | 0.5-4 |
| DOXYCYCLINE | S | <=0.1200 | 0.12-0.5 |
| ENROFLOXACIN | I | 1.0000 | 0.25-4 |
| ERYTHROMYCIN | I | 1.0000 | 0.25-4 |
| GENTAMICIN | R | | 4-16 |
| IMIPENEM | S | <=1.0000 | 1-4 |
| MARBOFLOXACIN | I | 2.0000 | 1-4 |
| MINOCYCLINE | S | <=0.5000 | 0.5-2 |
| NITROFURATOIN | S | <=16.0000 | 16-64 |
| OXACILLIN + 2% NACL | NI | >2.0000 | 0.25-2 |
| PENICILLIN | S | 2.0000 | 0.06-8 |
| PRADOFLOXACIN | NI | <=0.2500 | 0.25-2 |
| RIFAMPIN | S | <=1.0000 | 1-2 |
| TETRACYCLINE | S | <=0.2500 | 0.25-1 |
| TRIMETH/SULFA | NI | <=2.0000 | 2/38-4/76 |
| VANCOMYCIN | S | 2.0000 | 1-16 |

Kansas State Veterinary
DIAGNOSTIC LABORATORY


A: Enterococci are intrinsically resistant to aminoglycosides, cephalosporins, clindamycin, TMS

| | Interpretation | MIC | Test Range |
|-------------------|----------------|-----------|---------------|
| AMIKACIN | R | | 16-32 |
| AMOXI/CLAV | S | 0.5000 | 0.25/0.12-8/4 |
| AMPICILLIN | S | 1.0000 | 0.25-8 |
| CHLORAMPHENICOL | S | <=8.0000 | 8-32 |
| DOXYCYCLINE | S | <=0.1200 | 0.12-0.5 |
| ENROFLOXACIN | I | 1.0000 | 0.25-4 |
| ERYTHROMYCIN | I | 1.0000 | 0.25-4 |
| GENTAMICIN | R | | 4-16 |
| IMIPENEM | S | <=1.0000 | 1-4 |
| MARBOFLOXACIN | I | 2.0000 | 1-4 |
| MINOCYCLINE | S | <=0.5000 | 0.5-2 |
| NITROFURATOIN | S | <=16.0000 | 16-64 |
| OXACILLIN + 2% NA | NI | >2.0000 | 0.25-2 |
| PENICILLIN | S | 2.0000 | 0.06-8 |
| PRADOFLOXACIN | NI | <=0.2500 | 0.25-2 |
| RIFAMPIN | S | <=1.0000 | 1-2 |
| TETRACYCLINE | S | <=0.2500 | 0.25-1 |
| VANCOMYCIN | S | 2.0000 | 1-16 |

| | Interpretation | MIC | Test Range |
|-------------------|----------------|-----------|---------------|
| AMIKACIN | R | | 16-32 |
| AMOXI/CLAV | S | 0.5000 | 0.25/0.12-8/4 |
| AMPICILLIN | S | 1.0000 | 0.25-8 |
| CEFAZOLIN | R | >4.0000 | 2-4 |
| CEFOVECIN | NI | >8.0000 | 0.06-8 |
| CEFPODOXIME | NI | 4.0000 | 2-8 |
| CEPHALOTHIN | NI | >4.0000 | 2-4 |
| CHLORAMPHENICOL | S | <=8.0000 | 8-32 |
| CLINDAMYCIN | NI | >4.0000 | 0.5-4 |
| DOXYCYCLINE | S | <=0.1200 | 0.12-0.5 |
| ENROFLOXACIN | I | 1.0000 | 0.25-4 |
| ERYTHROMYCIN | I | 1.0000 | 0.25-4 |
| GENTAMICIN | R | | 4-16 |
| IMIPENEM | S | <=1.0000 | 1-4 |
| MARBOFLOXACIN | I | 2.0000 | 1-4 |
| MINOCYCLINE | S | <=0.5000 | 0.5-2 |
| NITROFURATOIN | S | <=16.0000 | 16-64 |
| OXACILLIN + 2% NA | NI | >2.0000 | 0.25-2 |
| PENICILLIN | S | 2.0000 | 0.06-8 |
| PRADOFLOXACIN | NI | <=0.2500 | 0.25-2 |
| RIFAMPIN | S | <=1.0000 | 1-2 |
| TETRACYCLINE | S | <=0.2500 | 0.25-1 |
| TRIMETH/SULFA | NI | <=2.0000 | 2/38-4/76 |
| VANCOMYCIN | S | 2.0000 | 1-16 |

Kansas State Veterinary
DIAGNOSTIC LABORATORY

C: Amoxicillin is the preferred therapy for Enterococcal infections



| | | | |
|------------|---|--------|--------|
| AMPICILLIN | S | 1.0000 | 0.25-8 |
|------------|---|--------|--------|

A or B?

History: Respiratory disease in an alpaca. *Pasteurella multocida* isolated on culture.

| | Interpretation | MIC | Test Range |
|-------------------|----------------|-----------|------------|
| AMPICILLIN | R | 8.0000 | 0.25 - 16 |
| CEFTIOFUR | NI | >8.0000 | 0.25 - 8 |
| CHLORTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| CLINDAMYCIN | NI | >16.0000 | 0.25 - 16 |
| DANOFLOXACIN | NI | 0.2500 | 0.12 - 1 |
| ENROFLOXACIN | NI | <=0.1200 | 0.12 - 2 |
| FLORFENICOL | S | 1.0000 | 0.25 - 8 |
| GENTAMICIN | S | <=1.0000 | 1 - 16 |
| NEOMYCIN | NI | <=4.0000 | 4 - 32 |
| OXYTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| PENICILLIN | NI | >8.0000 | 0.12 - 8 |
| SPECTINOMYCIN | NI | >64.0000 | 8 - 64 |
| SULFADIMETHOXINE | NI | >256.0000 | 256 |
| TIAMULIN | NI | >32.0000 | 0.5 - 32 |
| TILMICOSIN | NI | 16.0000 | 4 - 64 |
| TRIMETH/SULFA | S | <=2.0000 | 2/38 |
| TULATHROMYCIN | S | 2.0000 | 1 - 64 |
| TYLOSIN TARTRATE | NI | >32.0000 | 0.5 - 32 |


| | Interpretation | MIC | Test Range |
|-------------------|----------------|-----------|------------|
| AMPICILLIN | R | 8.0000 | 0.25 - 16 |
| CEFTIOFUR | NI | >8.0000 | 0.25 - 8 |
| CHLORTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| CLINDAMYCIN | NI | >16.0000 | 0.25 - 16 |
| DANOFLOXACIN | NI | 0.2500 | 0.12 - 1 |
| ENROFLOXACIN | NI | <=0.1200 | 0.12 - 2 |
| FLORFENICOL | S | 1.0000 | 0.25 - 8 |
| GENTAMICIN | S | <=1.0000 | 1 - 16 |
| NEOMYCIN | NI | <=4.0000 | 4 - 32 |
| OXYTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| PENICILLIN | NI | >8.0000 | 0.12 - 8 |
| SPECTINOMYCIN | NI | >64.0000 | 8 - 64 |
| SULFADIMETHOXINE | NI | >256.0000 | 256 |
| TIAMULIN | NI | >32.0000 | 0.5 - 32 |
| TRIMETH/SULFA | S | <=2.0000 | 2/38 |
| TULATHROMYCIN | S | 2.0000 | 1 - 64 |
| TYLOSIN TARTRATE | NI | >32.0000 | 0.5 - 32 |

Kansas State Veterinary
DIAGNOSTIC LABORATORY

B: Tilmicosin is potentially fatal in alpacas

| | Interpretation | MIC | Test Range |
|-------------------|----------------|-----------|------------|
| AMPICILLIN | R | 8.0000 | 0.25 - 16 |
| CEFTIOFUR | NI | >8.0000 | 0.25 - 8 |
| CHLORTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| CLINDAMYCIN | NI | >16.0000 | 0.25 - 16 |
| DANOFLOXACIN | NI | 0.2500 | 0.12 - 1 |
| ENROFLOXACIN | NI | <=0.1200 | 0.12 - 2 |
| FLORFENICOL | S | 1.0000 | 0.25 - 8 |
| GENTAMICIN | S | <=1.0000 | 1 - 16 |
| NEOMYCIN | NI | <=4.0000 | 4 - 32 |
| OXYTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| PENICILLIN | NI | >8.0000 | 0.12 - 8 |
| SPECTINOMYCIN | NI | >64.0000 | 8 - 64 |
| SULFADIMETHOXINE | NI | >256.0000 | 256 |
| TIAMULIN | NI | >32.0000 | 0.5 - 32 |
| TILMICOSIN | NI | 16.0000 | 4 - 64 |
| TRIMETH/SULFA | S | <=2.0000 | 2/38 |
| TULATHROMYCIN | S | 2.0000 | 1 - 64 |
| TYLOSIN TARTRATE | NI | >32.0000 | 0.5 - 32 |

| | Interpretation | MIC | Test Range |
|-------------------|----------------|-----------|------------|
| AMPICILLIN | R | 8.0000 | 0.25 - 16 |
| CEFTIOFUR | NI | >8.0000 | 0.25 - 8 |
| CHLORTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| CLINDAMYCIN | NI | >16.0000 | 0.25 - 16 |
| DANOFLOXACIN | NI | 0.2500 | 0.12 - 1 |
| ENROFLOXACIN | NI | <=0.1200 | 0.12 - 2 |
| FLORFENICOL | S | 1.0000 | 0.25 - 8 |
| GENTAMICIN | S | <=1.0000 | 1 - 16 |
| NEOMYCIN | NI | <=4.0000 | 4 - 32 |
| OXYTETRACYCLINE | NI | <=0.5000 | 0.5 - 8 |
| PENICILLIN | NI | >8.0000 | 0.12 - 8 |
| SPECTINOMYCIN | NI | >64.0000 | 8 - 64 |
| SULFADIMETHOXINE | NI | >256.0000 | 256 |
| TIAMULIN | NI | >32.0000 | 0.5 - 32 |
| TRIMETH/SULFA | S | <=2.0000 | 2/38 |
| TULATHROMYCIN | S | 2.0000 | 1 - 64 |
| TYLOSIN TARTRATE | NI | >32.0000 | 0.5 - 32 |



Questions?
Discussion?

Dr. Brian Lubbers
KSVDL
785-532-4012
blubbers@vet.k-state.edu



Kansas State Veterinary
DIAGNOSTIC LABORATORY

Kansas State Veterinary
DIAGNOSTIC LABORATORY



CLSI stuff

Developing Breakpoints

- *Breakpoint / Interpretive criteria*

- Minimal inhibitory concentration (MIC) used to indicate susceptible “S”, intermediate “I” or resistant “R”.
- ***Susceptible***
 - Category implies an infection that may be appropriately treated with the **dosage regimen** of an **antimicrobial agent** recommended for that **type of infection** and **infecting [bacterial] species [in that host animal species]**
- ***Intermediate***
 - Category implies an infection that may be appropriately treated in body sites where the drugs are physiologically concentrated, or when a high dosage of drug can be used
- ***Resistant***
 - Strains [in this category] are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules and/or fall in the range [of MICs] where specific microbial resistance mechanisms are likely and clinical outcome has not been predictable in effectiveness studies

Developing Breakpoints



1. Reproducible method and QC
2. Data needed to set a veterinary specific MIC breakpoint
 - a) Wild-type cut-off
 - b) PK/PD cut-off
 - c) Clinical cut-off
3. MIC – zone diameter correlation to set disk diffusion breakpoint


Does the Breakpoint still apply if.....

- Test conditions change....
 - Increase / decrease inoculum density
 - Incubate in CO₂
 - Use a different strength disk
 - Supplement testing media with serum
- Someone stores dry ice (for a 4th of July party) in the -80 freezer that holds your custom frozen AST panels

| Results for plate L1FBRP, organism S.aur 29213 | | |
|--|------------|--------------------------|
| Drug Descri... | MIC | Interpretation ▾ |
| Positive Gro... | - | Valid Growth Control |
| Tulathrom... | 128 | Out of Range High |
| Tildipirosin | 64 | Out of Range High |
| Spectinom... | 512 | Out of Range High |
| Ceftiofur | 0.25 | In Range |
| Florfenicol | 4 | In Range |
| Tilmicosin | 4 | In Range |
| Oxytetracycl... | <=0.12 | In Range |
| Enrofloxacin | 0.12 | In Range |

Developing Breakpoints


- Wild-type cut-off



Kansas State
DIAGNOSTICS


Does the Breakpoint still apply if.....

- I change the organism or antibiotic?



Developing Breakpoints

- PK/PD cut-off



Papich. 2010. AJVR. 71; 1484-1491.


Table 4. Probability of target attainment (PTA) for administration of cephalexin oral to dogs using Monte Carlo simulations.

| Drug and dose regimen | PTA from Monte Carlo simulation for the indicated MIC values | | | | | | | | |
|--|--|--------|-------|-------|-------|--------|--------|-------|----|
| | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 |
| Cephalexin in dogs (25 mg/kg oral) every 12 h | 98.7% | 97.93% | 94.8% | 89.6% | 72.9% | 47.05% | 14.03% | 1.74% | 0% |

Papich. 2018. JVDI. 30; 113-120.

Does the Breakpoint still apply if.....

- I change the antibiotic or the host species?
- I change the dosing regimen?



Does the Breakpoint still apply if.....


- I change to a different class of animal

Table 2A. Enterobacteriaceae (Continued)

| Test/Report Group | Body Site | Antimicrobial Agent | Organism | Disk Content | Zone Diameter Interpretive Criteria (nearest whole mm) | | | MIC Interpretive Criteria ($\mu\text{g/mL}$) | | | Comments |
|---------------------------------------|-----------|---------------------|---------------------------|------------------|--|-------|-----------|--|---|-----------|---|
| | | | | | S | I | R | S | I | R | |
| Aminoglycosides/Aminocyclitols | | | | | | | | | | | |
| Dogs | | | | | | | | | | | |
| A | | Amikacin | <i>E. coli</i> | – | – | – | – | ≤ 4 | 8 | ≥ 16 | (5) Breakpoints derived from microbiological, PK (using accepted clinical doses), and PD data. For dogs, the dose of amikacin modeled was 15 mg/kg, every 24 hours IM, IV, or SC. |
| A | | Gentamicin | <i>Enterobacteriaceae</i> | 10 μg | ≥ 16 | 13–15 | ≤ 12 | ≤ 2 | 4 | ≥ 8 | (6) Breakpoints derived from microbiological, PK (using accepted clinical doses), and PD data. For dogs, the dose of gentamicin modeled was 10 mg/kg every 24 hours IM. |
| Horses (Foals) | | | | | | | | | | | |
| A | | Amikacin | <i>E. coli</i> | – | – | – | – | ≤ 2 | 4 | ≥ 8 | (7) Breakpoints derived from microbiological, PK (using accepted clinical doses), and PD data. For foals <11 days of age, the dose of amikacin modeled was 20 mg/kg, every 24 hours IV. |
| Horses (Adults) | | | | | | | | | | | |
| A | | Amikacin | <i>E. coli</i> | – | – | – | – | ≤ 4 | 8 | ≥ 16 | (8) Breakpoints derived from microbiological, PK (using accepted clinical doses), and PD data. For adult horses, the dose of amikacin modeled was 10 mg/kg, every 24 hours, IM or IV. |

Developing Breakpoints


- Clinical cut-off



Kansas St
DIAGNOST

Does the Breakpoint still apply if.....

- I change the clinical disease process?




Kansas State Veterinary
DIAGNOSTIC LABORATORY

What do you think???

Most Dx labs report susceptibility summaries yearly. For example, Lab XYZ reported P. mult to be 85% susceptible to CTC. **As I understand CLSI has not established an S-I-R for CTC, only for parentally administered tetracyclines. If this is correct, Dx labs shouldn't report a CTC S-I-R for P. mult.** For parentally admin tetracyclines, the CLSI list 2 ug/ml as the MIC. If Dx labs are using 2.0 ug/ml at the MIC this is problematic in light of a 2009 Reinbold, et-al paper. [A 2009 study (REINBOLD, et-al. Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a feedlot setting. J. vet. Pharmacol. Therap. 33, 76–83) demonstrated the C-Max for CTC was 0.5 ug/ml.]

This makes me wonder if there is a disconnect between the CTC S-I-R Dx labs report for P mult and the pharmacokinetics of CTC in cattle.

Host species
Bacterial species
Dosing regimen
Disease process
Antibacterial



Kansas State Veterinary
DIAGNOSTIC LABORATORY

“Generic” BPs

...and how the micro lab can help!

- Older antimicrobials unlikely that a single sponsor will bring forth data to support a veterinary specific BP
- Use available literature to support BP development
 - Wild-type cutoff
 - PK-PD cutoff
 - Clinical cutoff



This is often needed by the CLSI “generic” working group.
Can diagnostic labs help with future BP development???

Why don't we have disk diffusion BPs?

- Disk diffusion BPs are developed by correlating the MIC to zone diameter using a process called “error rate bounding”
 - CLSI VET02
- MIC – zone diameter correlation not available for most (any?) “generic” BPs

Developing (disk diffusion) Breakpoints

Table 1. Guideline for Acceptable Discrepancy Rates (With Intermediate Ranges) (see Note)

| 1-dilution Intermediate Range | 2-dilution Intermediate Range | Discrepancy Rates | | |
|-------------------------------|---|-------------------|-------|-------|
| | | Very Major | Major | Minor |
| ≥ I+2 | ≥ I _{High} +2 | < 2% | N/A | < 5% |
| I+1 to I-1 | I _{High} +1 to I _{Low} -1 | <10% | <10% | < 40% |
| ≤ I-2 | ≤ I _{Low} -2 | N/A | <40% | < 5% |

| MIC Range | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | >35 | |
|-----------|----|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|--|
| I+3 ≥16 | 13 | 1 | 2 | 1 | 3 | 2 | 1 | | | | | | | | | | | | | | | | | | | | | | | | | |
| I+2 8.0 | 1 | | 1 | 3 | 1 | 2 | | | | 1 | 1 | 2 | | | 1 | | | | | | | | | | | | | | | | | |
| I+1 4.0 | | | | | 1 | 4 | 2 | 3 | 1 | | | | | | 1 | | | | | | | | | | | | | | | | | |
| I 2.0 | | | | | | | 1 | 2 | | 1 | 5 | 2 | 1 | 4 | 1 | | | 1 | | | | | | | | 1 | | | | | | |
| I-1 1.0 | | | | | | | | | | 3 | 5 | 5 | 7 | 3 | 3 | 3 | 1 | 2 | 1 | 3 | | | 1 | | | | | | | | | |
| I-2 0.5 | | | | 1 | | | | | | | 2 | 3 | 1 | 2 | 3 | 5 | 8 | 13 | 4 | 4 | 1 | | | 2 | 1 | | 1 | 1 | | | | |
| I-3 0.25 | | | | | | | | | | | | | 1 | 1 | 2 | 3 | 5 | 6 | 11 | 13 | 9 | 6 | 5 | 3 | 1 | 4 | 1 | | | | | |
| I-4 0.12 | | | | | | | | | | | | | | 1 | | | 1 | 6 | 13 | 9 | 6 | 7 | 6 | 1 | 3 | 1 | | | | | | |
| I-5 0.06 | | | | | | | | | | | | | | 1 | | | 1 | 4 | 5 | 6 | 5 | 4 | 3 | 8 | 10 | 5 | 7 | 3 | | 1 | | |
| I-6 ≤0.03 | | | | | | | | | | | | | | | | | | 3 | 7 | 17 | 20 | 20 | 9 | 15 | 12 | 10 | 10 | 1 | 1 | 6 | | |

Number of Discrepancies (Discrepancy Rate)

| MIC Range | Number | Very Major (%) | Major (%) | Minor (%) |
|----------------|------------|----------------------|----------------|-----------------|
| ≥ I + 2 | 36 | 1 (2.8) [†] | NA | 2 (5.6) |
| I + 1 to I - 1 | 66 | 1 (1.5) | 0 | 18 (27.3) |
| ≤ I - 2 | 393 | NA | 1 (0.3) | 2 (0.5) |
| Total | 495 | 2 (0.4) | 1 (0.2) | 22 (4.4) |

From CLSI M37 (now VET02)

What if there is NO BREAKPOINT???

I do not presume to tell other laboratories how to operate. In fact, I would not encourage you to adopt / do anything that is outside your "comfort zone".


I do NOT put any of the following on a report or create system rules that would make my suggestions seem like real breakpoints. I will use any / all of the following, but it is done on a one-on-one basis with the individual clinician.

Most of these strategies are aimed at identifying
"unreasonable" drug choices...
Rule-out drugs that won't work

What if there is NO BREAKPOINT???


1. Extrapolate a breakpoint from another animal species for that antimicrobial – pathogen combination
 - Historically, most common approach – use of human breakpoints
 - Concern with differences in pharmacokinetics

Florfenicol - Cattle



NADA 141-265: Nufloor Gold FOI


Florfenicol - Rabbits



Koc *et al.* (2009) Res Vet Sci, Vol 87(1); 102 - 105

What if there is NO BREAKPOINT???

2. Extrapolate a breakpoint from that host species and antimicrobial for another pathogen
 - Concern with MIC distribution match for the 2 bacterial species



What if there is NO BREAKPOINT???

3. Use an Epidemiological Cut-Off (ECV / ECOFF)

- Not a clinical breakpoint, but may suggest if a resistance element is present

Antimicrobial wild type distributions of microorganisms

Search

Method: MIC Disk diffusion

Antimicrobial: Antimicrobial... Species: *Pasteurella multocida* Disk content: Disk content...

Species: *Pasteurella multocida* (Method: MIC)

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance

| | 0.002 | 0.004 | 0.008 | 0.016 | 0.032 | 0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | ECOFF | Distributions | Observations |
|------------------|-------|-------|-------|-------|-------|-------|-------|------|-----|-----|-----|-----|-----|----|----|----|-----|-----|-----|-------|---------------|--------------|
| Amoxicillin | 0 | 0 | 0 | 0 | 0 | 13 | 35 | 104 | 90 | 2 | 1 | 2 | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 1.0 | 6 | 251 |
| Ampicillin | 0 | 0 | 0 | 0 | 0 | 4 | 40 | 120 | 35 | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 1.0 | 6 | 226 |
| Benzylpenicillin | 0 | 0 | 0 | 0 | 14 | 60 | 124 | 75 | 1 | 2 | 7 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0.5 | 6 | 292 |
| Cefotaxime | 1 | 15 | 103 | 35 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.032 | 4 | 157 |
| Chloramphenicol | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 107 | 139 | 45 | 10 | 9 | 44 | 18 | 6 | 1 | 0 | 0 | 0 | 2.0 | 5 | 393 |
| Ciprofloxacin | 0 | 9 | 61 | 135 | 17 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.064 | 6 | 227 |
| Doxycycline | 0 | 0 | 0 | 0 | 0 | 2 | 51 | 218 | 40 | 12 | 12 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1.0 | 5 | 338 |
| Enrofloxacin | 0 | 8 | 33 | 14 | 6 | 1 | 1 | 0 | 26 | 20 | 6 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | ND | 3 | 117 |
| Florfenicol | 0 | 0 | 0 | 0 | 0 | 6 | 50 | 202 | 378 | 98 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.0 | 6 | 705 |
| Flumequine | 0 | 0 | 0 | 0 | 1 | 73 | 56 | 80 | 14 | 6 | 3 | 4 | 0 | 68 | 4 | 46 | 0 | 0 | 0 | ND | 5 | 357 |
| Gentamicin | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 5 | 27 | 118 | 225 | 90 | 45 | 29 | 67 | 45 | 4 | 0 | 0 | 8.0 | 7 | 659 |
| Kanamycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 26 | 44 | 83 | 108 | 61 | 10 | 20 | 10 | 7 | 0 | ND | 2 | 373 |
| Neomycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 32 | 66 | 169 | 84 | 93 | 64 | 54 | 19 | 0 | 0 | ND | 6 | 589 |
| Oxytetracycline | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 15 | 35 | 28 | 37 | 5 | 1 | 2 | 6 | 0 | 0 | 0 | 0 | ND | 1 | 139 |
| Spectinomycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 28 | 88 | 29 | 0 | 1 | 6 | 0 | 4 | 160 |
| | 0.002 | 0.004 | 0.008 | 0.016 | 0.032 | 0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | ECOFF | Distributions | Observations |
| Tetracycline | 0 | 0 | 0 | 0 | 0 | 3 | 37 | 411 | 853 | 299 | 130 | 31 | 51 | 76 | 67 | 26 | 2 | 0 | 1 | 2.0 | 19 | 1967 |
| Thiamphenicol | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 101 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 3 | 0 | ND | 1 | 140 |
| Tilmicosin | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 22 | 28 | 53 | 135 | 120 | 77 | 25 | 24 | 17 | 15 | 9 | 4 | ND | 6 | 533 |

Kan
DIAC


Am-

What if there is NO BREAKPOINT???

4. Use in-house data to create an ECV



Moraxella – Oxytetracycline MIC distribution



| | MORAXELLA SP. - 1 |
|-------------------|--------------------------|
| AMPICILLIN | NI ≤=0.2500(0.25 - 16) |
| CEFTIOFUR | NI ≤=0.2500(0.25 - 8) |
| CHLORTETRACYCLINE | NI ≤=0.5000(0.5 - 8) |
| CLINDAMYCIN | NI 2.0000(0.25 - 16) |
| FLORFENICOL | NI 0.5000(0.25-8) |
| GENTAMICIN | S ≤=1.0000(1-16) |
| NEOMYCIN | NI ≤=4.0000(4-32) |
| OXYTETRACYCLINE | NI ≤=0.5000(0.5-8) |
| PENICILLIN | NI ≤=0.1200(0.12-8) |
| SPECTINOMYCIN | NI ≤=8.0000(8-64) |
| SULPHADIMETHOXINE | NI ≤=256.0000(256) |
| TIAMULIN | NI ≤=0.5000(0.5-32) |
| TILMICOSIN | NI ≤=4.0000(4-64) |
| TRIMETH/SULFA | S ≤=2.0000(2/38) |
| TULATHROMYCIN | NI ≤=1.0000(1-64) |
| TYLOSIN TARTRATE | NI 4.0000(0.5-32) |

What if there is NO BREAKPOINT???

- (Cautiously) Use published MIC distribution data
 - Attention to methodology

Mycoplasma MIC distributions – CO₂ incubation???




Figure 2 MIC distribution of the Hungarian isolates for each antibiotic tested in this study. Arrows indicate the MIC50 and MIC90 values.

Kan
DIA

Kansas State Veterinary
DIAGNOSTIC LABORATORY

Other CLSI stuff



- VAST is always looking for MIC distribution data
- Next meeting – Jan 24-29, 2019 – St. Augustine, FL
- New revision of VET01
- New revision of VET08
- VET09

Other Questions? Discussion?

Dr. Brian Lubbers
KSVDL
785-532-4012
blubbers@vet.k-state.edu



Kansas State Veterinary
DIAGNOSTIC LABORATORY